HER2 has been found to be overexpressed, as determined by both IHC and GCN analyses, in 7–25 % of gastric adenocarcinomas [11, 12, 17, 19] including all histological subtypes, which is comparable with our finding that high HER2 protein expression was found in 14.1 % and HER2 gene amplification in 13.2 % of intestinal adenocarcinomas. The gene discussed is ERBB2; the disease is gastric adenocarcinoma.